Crinetics Pharmaceuticals (CRNX) Investor Presentation - Slideshow

Paltusotine (SST2 Agonist) - Crinetics is developing Paltusotine, a potential first-in-class oral nonpeptide SST2 agonist, for Acromegaly, Carcinoid Syndrome, and Nonfunctional Neuroendocrine Tumors[13] - The US prevalence for Acromegaly is 26,000, Carcinoid Syndrome is 33,000, and Nonfunctional NETs is 138,000[9, 14] - Phase 2 ACROBAT Edge study met the primary endpoint, maintaining hormone suppression after switching from injected standard of care to oral paltusotine[36] - Phase 3 program is designed to support potential for broad first-line medical therapy in acromegaly patients[42] CRN04894 (ACTH Antagonist) - Crinetics is developing CRN04894, a potential first-in-class oral nonpeptide ACTH antagonist, for Congenital Adrenal Hyperplasia (CAH) and Cushing's Disease (CD)[45] - The US prevalence for Cushing's Disease is 10,000 and for Congenital Adrenal Hyperplasia (CAH) is 27,000[9, 52] - Phase 1 SAD data showed strong suppression of basal cortisol (56% at 80 mg dose)[69, 76] CRN04777 (SST5 Agonist) - Crinetics is developing CRN04777, a potential first-in-class oral nonpeptide SST5 agonist, for Congenital Hyperinsulinism (HI)[81] - Phase 1 SAD data showed dose-dependent reduction in glucose-induced insulin secretion and reversal of sulfonylurea-induced insulin secretion[110] Market and Financials - The market for Acromegaly and NETs is approximately $3 billion despite limitations of current therapies[16]